Artios Pharma Announces Appointment of Professor Rajesh Chopra as Non-Executive Director

Cambridge, UK, 11 February 2019. Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing a broad pipeline of innovative treatments for cancer, today announced the appointment of Professor Rajesh Chopra as Non-Executive Director (NED).

In an exceptional career in Pharmaceutical R&D Professor Chopra has held a number of distinguished roles including Corporate Vice President of Translational Research at Celgene, where he led US and European teams of scientists in San Diego, San Francisco and Seville, and clinicians involved in taking agents from discovery to proof-of-concept clinical trials in oncology and immune/inflammatory diseases, as well as in stem cell therapies. From 2004–09 he was part of the Oncology leadership team at AstraZeneca where he established the Translational Medicine Group in Boston, Massachusetts, USA. There he was involved in taking six small molecules and two antibodies from discovery into clinical trials.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH